Acumen Pharmaceuticals Statistics
 Total Valuation
 ABOS has a market cap or net worth of $134.47 million. The enterprise value is -$1.59 million.
 Important Dates
 The next estimated earnings date is Tuesday, November 11, 2025, before market open.
 | Earnings Date | Nov 11, 2025 | 
| Ex-Dividend Date | n/a | 
Share Statistics
 ABOS has 60.57 million shares outstanding. The number of shares has increased by 3.87% in one year.
 | Current Share Class | 60.57M | 
| Shares Outstanding | 60.57M | 
| Shares Change (YoY) | +3.87% | 
| Shares Change (QoQ) | +0.08% | 
| Owned by Insiders (%) | 10.92% | 
| Owned by Institutions (%) | 33.24% | 
| Float | 35.61M | 
Valuation Ratios
  | PE Ratio | n/a | 
| Forward PE | n/a | 
| PS Ratio | n/a | 
| Forward PS | n/a | 
| PB Ratio | 1.15 | 
| P/TBV Ratio | 1.15 | 
| P/FCF Ratio | n/a | 
| P/OCF Ratio | n/a | 
| PEG Ratio | n/a | 
 Financial Ratio HistoryEnterprise Valuation
  | EV / Earnings | n/a | 
| EV / Sales | n/a | 
| EV / EBITDA | n/a | 
| EV / EBIT | n/a | 
| EV / FCF | n/a | 
Financial Position
 The company has a current ratio of 5.97, with a Debt / Equity ratio of 0.26.
 | Current Ratio | 5.97 | 
| Quick Ratio | 5.79 | 
| Debt / Equity | 0.26 | 
| Debt / EBITDA | n/a | 
| Debt / FCF | n/a | 
| Interest Coverage | -34.84 | 
Financial Efficiency
 Return on equity (ROE) is -75.71% and return on invested capital (ROIC) is -42.77%.
 | Return on Equity (ROE) | -75.71% | 
| Return on Assets (ROA) | -39.06% | 
| Return on Invested Capital (ROIC) | -42.77% | 
| Return on Capital Employed (ROCE) | -97.92% | 
| Revenue Per Employee | n/a | 
| Profits Per Employee | -$2.24M | 
| Employee Count | 61 | 
| Asset Turnover | n/a | 
| Inventory Turnover | n/a | 
Taxes
  | Income Tax | n/a | 
| Effective Tax Rate | n/a | 
Stock Price Statistics
 The stock price has decreased by -23.58% in the last 52 weeks. The beta is 0.20, so ABOS's price volatility has been lower than the market average.
 | Beta (5Y) | 0.20 | 
| 52-Week Price Change | -23.58% | 
| 50-Day Moving Average | 1.68 | 
| 200-Day Moving Average | 1.36 | 
| Relative Strength Index (RSI) | 60.05 | 
| Average Volume (20 Days) | 439,927 | 
Short Selling Information
 The latest short interest is 1.33 million, so 2.20% of the outstanding shares have been sold short.
 | Short Interest | 1.33M | 
| Short Previous Month | 1.31M | 
| Short % of Shares Out | 2.20% | 
| Short % of Float | 3.74% | 
| Short Ratio (days to cover) | 2.70 | 
Income Statement
  | Revenue | n/a | 
| Gross Profit | -124.21M | 
| Operating Income | -143.98M | 
| Pretax Income | -136.67M | 
| Net Income | -136.67M | 
| EBITDA | -143.92M | 
| EBIT | -143.98M | 
| Earnings Per Share (EPS) | -$2.27 | 
 Full Income StatementBalance Sheet
 The company has $143.37 million in cash and $30.10 million in debt, giving a net cash position of $136.07 million or $2.25 per share.
 | Cash & Cash Equivalents | 143.37M | 
| Total Debt | 30.10M | 
| Net Cash | 136.07M | 
| Net Cash Per Share | $2.25 | 
| Equity (Book Value) | 117.08M | 
| Book Value Per Share | 1.93 | 
| Working Capital | 123.54M | 
 Full Balance SheetCash Flow
 In the last 12 months, operating cash flow was -$117.76 million and capital expenditures -$88,000, giving a free cash flow of -$117.85 million.
 | Operating Cash Flow | -117.76M | 
| Capital Expenditures | -88,000 | 
| Free Cash Flow | -117.85M | 
| FCF Per Share | -$1.95 | 
 Full Cash Flow StatementMargins
  | Gross Margin | n/a | 
| Operating Margin | n/a | 
| Pretax Margin | n/a | 
| Profit Margin | n/a | 
| EBITDA Margin | n/a | 
| EBIT Margin | n/a | 
| FCF Margin | n/a | 
Dividends & Yields
 ABOS does not appear to pay any dividends at this time.
 | Dividend Per Share | n/a | 
| Dividend Yield | n/a | 
| Dividend Growth (YoY) | n/a | 
| Years of Dividend Growth | n/a | 
| Payout Ratio | n/a | 
| Buyback Yield | -3.87% | 
| Shareholder Yield | -3.87% | 
| Earnings Yield | -101.63% | 
| FCF Yield | -87.64% | 
 Analyst Forecast
 The average price target for ABOS is $8.00, which is 260.36% higher than the current price. The consensus rating is "Strong Buy".
 | Price Target | $8.00 | 
| Price Target Difference | 260.36% | 
| Analyst Consensus | Strong Buy | 
| Analyst Count | 3 | 
| Revenue Growth Forecast (5Y) | n/a | 
| EPS Growth Forecast (5Y) | n/a | 
 Stock ForecastsFair Value
 There are several formulas that can be used to estimate the intrinsic value of a stock.
 | Lynch Fair Value | n/a | 
| Lynch Upside | n/a | 
| Graham Number | n/a | 
| Graham Upside | n/a | 
Stock Splits
 This stock does not have any record of stock splits.
 | Last Split Date | n/a | 
| Split Type | n/a | 
| Split Ratio | n/a | 
Scores
  | Altman Z-Score | n/a | 
| Piotroski F-Score | 1 |